Allosteric Modulation: How Peptides Change Receptors

How Peptides Activate GPCRs

3 Types of Allosteric Modulators

Allosteric modulators bind receptors at sites distinct from where the natural ligand attaches, allowing them to enhance, diminish, or redirect signaling without directly competing for the active site.

Conn et al., Annual Review of Pharmacology and Toxicology, 2009

Conn et al., Annual Review of Pharmacology and Toxicology, 2009

View as image

Every receptor has an active site where its natural ligand binds. This is the orthosteric site: the "front door" of the receptor. Allosteric modulation works through a different entrance entirely. An allosteric modulator binds to a separate location on the same receptor, changing the receptor's shape and altering how it responds to its natural ligand. For the basics of how peptides interact with receptors through the orthosteric site, see How Peptides Activate G-Protein Coupled Receptors: The Signaling Cascade.

This distinction matters for drug design. Orthosteric drugs replace or block the natural signal. Allosteric modulators adjust the volume on a signal that is already there. That difference has profound implications for selectivity, safety, and the types of therapeutic effects that are achievable.

The Orthosteric vs Allosteric Distinction

The orthosteric site is the binding pocket shaped by evolution to receive a specific endogenous ligand. For peptide receptors, this is where the peptide hormone or neuropeptide attaches: GLP-1 at the GLP-1 receptor, ghrelin at GHS-R1a, angiotensin II at AT1R. Most conventional drugs target this site. An agonist mimics the natural ligand; an antagonist blocks it.

The allosteric site is any other location on the receptor where a molecule can bind and influence function. The word comes from the Greek "allos" (other) and "stereos" (shape). When a molecule binds allosterically, it changes the receptor's three-dimensional conformation, which in turn changes how the orthosteric site behaves. The natural ligand's ability to bind, the efficiency of signal transduction, and even which downstream pathways are activated can all shift.

This is not a theoretical curiosity. Endogenous allosteric modulators are everywhere in biology. Ions, lipids, other proteins, and even other peptides can act allosterically. The receptor is not a simple lock-and-key mechanism; it is a flexible molecular machine with multiple control surfaces. Understanding allosteric modulation is essential for understanding how peptide receptors actually behave in living systems, where multiple signals converge on the same receptor simultaneously.

The Three Types of Allosteric Modulators

Positive allosteric modulators (PAMs) increase the receptor's response to its natural ligand. A PAM does not activate the receptor on its own (in the pure case). Instead, it makes the orthosteric agonist more effective. The result: enhanced signaling when the natural signal is present, but no activation when the signal is absent. This "use-dependent" property is one of the key advantages of PAMs over direct agonists for drug design. It preserves the natural timing and patterning of signaling.

Andresen et al. (2023) identified novel small molecule allosteric enhancers of guanylyl cyclase-A (GC-A), the receptor for atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP). These compounds enhanced ANP and BNP effects in cellular systems expressing GC-A, demonstrating that even large receptor complexes like guanylyl cyclases are amenable to allosteric enhancement.^[1]

Negative allosteric modulators (NAMs) reduce the receptor's response. A NAM can decrease the affinity of the orthosteric ligand, reduce the maximal signaling capacity, or both. Ferre et al. (2023) discovered that sodium ions act as a natural negative allosteric regulator of the ghrelin receptor (GHS-R1a). Using sodium-23 NMR spectroscopy, molecular dynamics simulations, and mutagenesis, they demonstrated that sodium binds to a conserved allosteric site in the receptor's transmembrane core, reducing the receptor's constitutive (baseline) activity.^[2] This finding means that extracellular sodium concentration, which varies with hydration status, may influence ghrelin signaling in vivo.

Neutral allosteric ligands (NALs) bind to the allosteric site without changing the receptor's signaling. While they appear pharmacologically inert, they block other molecules from occupying the same allosteric site. NALs can serve as research tools to map allosteric binding pockets and as starting points for drug design.

Peptides as Allosteric Modulators

Peptides can both be the target of allosteric modulation and function as allosteric modulators themselves.

Growth Hormone Secretagogues: A Case Study

The ghrelin receptor (GHS-R1a) provides one of the best-studied examples of peptide-related allosteric pharmacology. Holst et al. (2005) demonstrated that non-peptide (MK-677) and peptide (hexarelin, GHRP-6) growth hormone secretagogues act as both direct ghrelin receptor agonists and allosteric modulators of ghrelin binding. Some enhanced ghrelin's binding affinity (positive allosteric effect) while others reduced it (negative allosteric effect), despite all being agonists at the orthosteric site.^[3]

This dual mechanism complicates the pharmacology of growth hormone secretagogues in ways that are often overlooked in popular discussions of these peptides. A compound like hexarelin is not simply "a ghrelin receptor agonist." It simultaneously activates the receptor and changes how the receptor responds to the body's own ghrelin. Bennett et al. (2009) further demonstrated that peptidyl and non-peptidyl GH secretagogues acted as "orthosteric super-agonists" at GHS-R1a, exceeding ghrelin's own maximal receptor activation rather than acting as pure allosteric modulators.^[4]

Holst et al. (2009) mapped the binding sites more precisely, showing that ghrelin, synthetic agonists, and ago-allosteric modulators all bind overlapping sites on the ghrelin receptor, competing for the same binding pocket rather than occupying distinct allosteric locations.^[5] This finding illustrates a common complexity: the distinction between orthosteric and allosteric binding is not always clean. Some molecules access both sites, and the receptor's flexible structure means that binding at one location can reshape distant regions. For more on how ghrelin itself functions, see Ghrelin: The Hunger Hormone That Rises Before Meals.

Stapled Peptides Targeting Allosteric Sites

Fulton et al. (2018) demonstrated a different approach: designing peptides specifically to target an allosteric site. Their stapled peptide EHBI2 was engineered to mimic the H-helix of the EGFR kinase domain, disrupting the asymmetric kinase dimer interface required for EGFR activation. The peptide inhibited EGFR at concentrations as low as 10 micromolar, with approximately 75% inhibition of A431 cell proliferation.^[6] This is not a traditional receptor-ligand interaction. The stapled peptide works by preventing two copies of the same kinase from forming the active dimer, a fundamentally allosteric mechanism.

Kumar et al. (2017) took yet another approach, designing the tripeptide CWR (Cys-Trp-Arg) as an allosteric activator of the enzyme SIRT1, a deacetylase linked to longevity pathways. The tripeptide enhanced SIRT1 activity in biochemical assays and cellular models, with downstream effects on p53 deacetylation and tumor suppression.^[7] While SIRT1 is an enzyme rather than a receptor, the principle is identical: a short peptide binds at a site distant from the catalytic center and modulates function.

Why Allosteric Modulation Matters for Drug Design

The pharmaceutical interest in allosteric modulators stems from several practical advantages over orthosteric drugs.

Selectivity. Many peptide receptors belong to large families with highly conserved orthosteric sites. The GLP-1 receptor, glucagon receptor, and GIP receptor, for example, share structural features in their peptide-binding domains. An allosteric site, by contrast, is often unique to a specific receptor subtype. This means allosteric modulators can achieve selectivity that orthosteric drugs cannot, reducing off-target effects. For more on how GLP-1 and related receptors differ despite their similarities, see Short-Acting vs Long-Acting GLP-1 Agonists: What's the Difference?.

Preserved signaling patterns. A PAM enhances signaling only when the endogenous ligand is present. This means it preserves the natural pulsatile, circadian, and stimulus-dependent patterns of hormone signaling. A direct agonist, by contrast, provides continuous activation regardless of physiological context. This difference can matter for receptors where the timing of signaling is as important as its magnitude. See Receptor Desensitization: Why Peptide Effects Wear Off Over Time for how continuous vs pulsatile activation leads to different receptor fates.

Ceiling effect. PAMs generally have an intrinsic ceiling: they cannot drive receptor activation beyond the maximum achievable by the endogenous ligand plus the modulator. This built-in ceiling reduces overdose risk compared to direct agonists, which can drive signaling to supraphysiological levels.

Pathway selectivity. Some allosteric modulators preferentially enhance one downstream pathway over another. This connects directly to Biased Agonism: Why the Same Receptor Can Produce Different Effects. Hadjadj et al. (2026) demonstrated this principle by designing C-terminal modifications of angiotensin II peptide analogs that produced tunable biased signaling at the AT1 receptor, achieving beta-arrestin engagement with minimal Gq activation, resulting in enhanced cardiac function with limited blood pressure elevation in rats.^[8]

Current Limitations

The allosteric approach has not yet transformed peptide therapeutics the way it has transformed some small-molecule drug classes. As of 2026, four small-molecule allosteric GPCR modulators have received FDA approval, starting with cinacalcet (a positive allosteric modulator of the calcium-sensing receptor) in 2004. None of the approved allosteric modulators are themselves peptides.

The challenges are real. Allosteric sites are harder to identify and characterize than orthosteric sites. The binding pockets are often shallow and transient, making structure-based drug design difficult. Many allosteric effects are subtle and context-dependent, complicating clinical development. And the "probe dependence" problem means that an allosteric modulator's effect can change depending on which orthosteric ligand is present. What enhances one agonist may have no effect on another.

For peptide-based allosteric modulators specifically, the additional challenges of peptide drug delivery (proteolytic degradation, poor oral bioavailability, limited blood-brain barrier penetration) apply on top of the allosteric-specific hurdles. Schuss et al. (2026) identified a pathway-independent positive allosteric modulator called C1 that allows for receptor activation studies across multiple signaling pathways, potentially addressing some of the probe-dependence challenges.^[9]

The field is moving toward hybrid approaches. Ago-allosteric modulators that combine direct agonism with allosteric modulation, biased allosteric modulators that redirect signaling pathways, and bitopic ligands that simultaneously occupy orthosteric and allosteric sites represent the next generation of peptide receptor pharmacology.

The Bottom Line

Allosteric modulation allows molecules to fine-tune receptor signaling by binding at sites separate from the natural ligand's binding pocket. Research on the ghrelin receptor has revealed that growth hormone secretagogues function as both agonists and allosteric modulators simultaneously. The pharmaceutical advantages of allosteric approaches include improved selectivity, preserved signaling patterns, and built-in safety ceilings. Peptide-specific applications are still early-stage, but stapled peptides and designed tripeptides have demonstrated that short peptides can effectively target allosteric sites on both receptors and enzymes.

Frequently Asked Questions

What is allosteric modulation in simple terms?

Allosteric modulation is when a molecule binds to a receptor at a site separate from where the natural signal attaches, changing how the receptor responds to that signal. Rather than replacing or blocking the signal directly, the allosteric modulator adjusts the receptor's sensitivity. It is like turning a volume knob on a radio rather than changing the station. The natural signal is still there, but the receptor responds to it differently.

What is the difference between allosteric and orthosteric binding?

Orthosteric binding occurs at the receptor's primary active site, where the natural ligand (such as a peptide hormone) normally attaches. Allosteric binding occurs at a separate location on the same receptor. Orthosteric drugs directly mimic or block the natural ligand, while allosteric modulators change the receptor's shape to indirectly influence how it responds to its natural ligand. This distinction allows allosteric drugs to achieve effects that orthosteric drugs cannot.

What is a positive allosteric modulator?

A positive allosteric modulator (PAM) is a molecule that enhances a receptor's response to its natural ligand. A PAM does not activate the receptor by itself (in the pure case). Instead, it increases the natural signal's potency or efficacy. This "use-dependent" property means the enhancement occurs only when the natural signal is present, preserving the body's normal signaling timing and patterns.

Are any allosteric modulators FDA approved?

Four small-molecule allosteric modulators of GPCRs have received FDA approval as of 2026. The first was cinacalcet (Sensipar), a positive allosteric modulator of the calcium-sensing receptor approved in 2004 for hyperparathyroidism. None of the currently approved allosteric modulators are peptides, though peptide-based allosteric approaches are in preclinical development for targets including EGFR and SIRT1.

Can peptides act as allosteric modulators?

Yes. Research has demonstrated that peptides can function as allosteric modulators in several contexts. Growth hormone secretagogues like hexarelin act as both direct agonists and allosteric modulators at the ghrelin receptor (Holst et al., 2005). Stapled peptides have been designed to target allosteric interfaces on kinases like EGFR (Fulton et al., 2018). And designed tripeptides like CWR can allosterically activate enzymes such as SIRT1 (Kumar et al., 2017).

Why are allosteric modulators better than regular drugs?

Allosteric modulators offer several advantages: greater selectivity between closely related receptor subtypes, preservation of natural signaling patterns (they only work when the endogenous signal is present), a built-in ceiling effect that limits overdose risk, and the ability to selectively enhance specific signaling pathways. These properties do not make them universally "better," but they address specific limitations of orthosteric drugs, particularly for receptor families where selectivity is difficult to achieve.